Inovio Pharmaceuticals Inc
INO - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$154.26M
Close$
$0.74
60.9% downside
Current Fair Value
60.9% downsideOvervalued by 60.9% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $154.26 Million |
|---|---|
| Enterprise Value | $130.74 Million |
| Earnings per Share | $-1.81 |
| Beta | 1.61 |
| Outstanding Shares | 81,619,113 |
Return
| Return on Equity | -1942959.72% |
|---|---|
| Return on Assets | -171956.37% |
| Return on Invested Capital | -916221.94% |
Valuation & Multiples
| P/E Ratio | -0.52 |
|---|---|
| PEG | 0.69 |
| Price to Sales | -1.89 |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | -2000.76 |
| Enterprise Value to EBIT | 0 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.06 |
| Debt to Equity | 1.83 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 12, 2026
EPS Estimate
$-0.22
Consensus analyst estimateRevenue Estimate
$533,333
Consensus analyst estimateNext Earnings Call
Expected Date
November 9, 2026
EPS Estimate
$-0.24
Consensus analyst estimateRevenue Estimate
$2.27 M
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.0000▼ 4.93% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.01%▼ 41.84% |
|---|---|
| Total Invested | $6,557▼ 99.98% |
| Investors Holding | 8▼ 105.00% |
About Inovio Pharmaceuticals Inc
112 employees
CEO: Jong Kim
Inovio Pharmaceuticals, Inc. is a biotechnology firm focused on researching, developing, and bringing to market DNA-based treatments designed to address and safeguard individuals from conditions linked to human papillomavirus (HPV), vari...